Combination of PARP Inhibitor and Antiangiogenic Therapy Following Disease Progression in Patients With Epithelial Ovarian Cancer Undergoing PARP Inhibitor Maintenance Therapy: A Real‐World Study
ABSTRACT
Objective
To investigate whether the combination of antiangiogenic therapy and poly‐ADP‐ribose polymerase inhibitors (PARPi) can enhance the effectiveness of maintenance therapy in patients with progressive ovarian cancer who are progressing after PARPi maintenance therapy.
Design
Retrospective cohort study.
Setting
Single‐centre tertiary hospital in Beijing, China.
Population
Patients treated with combination therapy.
Methods
We retrospectively reviewed the clinicopathological data of patients with epithelial ovarian cancer. Telephone follow‐ups were performed for eligible participants to verify disease progression and survival status.
Main Outcome Measures
Clinical endpoints included objective response rate (ORR), disease control rate (DCR), time‐to‐symptomatic progression (TTSP), and progression‐free survival.
Results
Overall, 25 patients were analysed. Overall confirmed ORR was 44%, and the DCR was 68%. The median TTSP was 12.0 months (95% CI: 2.05–24.73). In the progression‐free interval (PFI) > 12 months group (n = 15), the ORR was 60% (9/15), and the DCR was 73.3%. In the PFI ≤ 12 months group (n = 10), the ORR was 20% (2/10), and the DCR was 60%. The median TTSP was not reached in the PFI > 12 months group and was 4.0 months (95% CI: 2.988–5.012) for the PFI ≤ 12 months group. The 6‐month progression‐free survival rates were 58% and 40%, respectively. Among the 10 patients who received subsequent chemotherapy, seven achieved partial response (PR), and one had stable disease. The respective ORR and DCR values were 70% and 80%.
Conclusions
Combining antiangiogenic therapy with the original PARPi may benefit patients with ascites‐free ovarian cancer and a low tumour burden who experience disease progression following PARPi maintenance therapy.